Independent Researchers Reaffirm REQORSA’s Potential in Cancer, Suggest REQORSA May Benefit Other Diseases and Infections

A new study publishedin Cancer Gene Therapy by independent researchers outlines REQORSA as a promising therapeutic candidate for combinational therapy in cancer

Independent researchers at Meharry Medical College and Vanderbilt University recently published a study in Cancer Gene Therapy titled, “Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications.”

The study provides an overview of TUSC2 (sometimes referred to as FUS1), which is the tumor suppressor gene used in Genprex’s REQORSA™ Immunogene Therapy. The study highlights TUSC2’s mechanism of action, the preclinical and clinical data of REQORSA in non-small cell lung cancer, and REQORSA’s ability to be combined with targeted therapies and immunotherapies; thus serving as an outside, unbiased affirmation to REQORSA and its potential as a therapeutic candidate in cancer.

Some of the study’s key highlights and supporting evidence of TUSC2 and Genprex’s clinical strategies include:

  • The deletion of TUSC2 in lung cancer – “FUS1/TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer.” In fact, approximately 80% of all lung cancers lack or have low levels of the TUSC2 tumor suppressor protein.
  • TUSC2’s Mechanisms of Action – “FUS1/TUSC2 induces cancer cell death, increases apoptosis and inhibits cell proliferation.”
  • Drug Resistance – “Conventional therapy for metastatic NSCLC currently uses epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors such as osimertinib. Beside toxicity, this type of therapy often leads to treatment-resistant cancer as a result of selecting tumor cell clones carrying mutations, thus leading to drug resistance.” In addition to targeted therapies, “effectiveness of immunotherapeutics is limited due to evasion of tumor cells from immunosurveillance mechanisms eventually leading to tumor resistance similar to chemotherapy.”
  • TUSC2 as a Combination Therapy – On targeted therapies: “Ability of FUS1/TUSC1 to suppress receptor and non-receptor kinases as well as sensitize NSCLC cells to chemotherapeutics makes this tumor suppressor a promising therapeutic candidate for combinational therapy.” On immunotherapies: “REQORSA and anti-PD-1 combined therapy demonstrated significantly stronger immune response than individual therapies.” On chemotherapy: “FUS1/TUSC2 is a promising adjuvant for successful anti-tumor chemotherapy.”
  • TUSC2 May Benefit Many Types of Cancer – “The localization of tumor suppressor genes in the 3p21 region was reinforced by detection of deletions in this area in other solid (breast, cervix, and renal carcinoma) and hematopoietic (chronic myeloid leukemia) tumors.”
  • TUSC2 May Benefit Other Diseases and Infections – “FUS1-dependent mechanisms are relevant in etiologies of diseases beyond cancer, such as chronic inflammation, bacterial and viral infections, premature aging, and geriatric diseases.”

To read the article in its entirety, click here. For more information and additional studies supporting TUSC2, please refer to our Bibliography Page.

This research paper was not sponsored Genprex and the Company has no affiliation with the researchers or the research paper.

Cautionary Language Concerning Forward-Looking Statements 

Statements contained in this blog post regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K and “Part II, Item 1A” of Genprex’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses. 

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this blog post. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this blog post or to reflect the occurrence of unanticipated events, except as required by law.